{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:00Z","timestamp":1788869340480,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.beem.2026.102082","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:10:35Z","timestamp":1769793035000},"page":"102082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypopituitarism in patients with prolactinomas: a narrative review"],"prefix":"10.1016","volume":"40","author":[{"given":"Claudia","family":"Campana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2026.102082_bib1","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/S0140-6736(24)00342-8","article-title":"Hypopituitarism","volume":"403","author":"Fleseriu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2026.102082_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-016-1159-3","article-title":"Mortality in adults with hypopituitarism: a systematic review and meta-analysis","volume":"56","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib5","unstructured":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | The BMJ n.d. \u3008https:\/\/www.bmj.com\/content\/372\/bmj.n71\u3009 (accessed January 6, 2026)."},{"key":"10.1016\/j.beem.2026.102082_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1705300","article-title":"Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery","volume":"16","author":"Prinzi","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.967407","article-title":"Prolactinomas in adolescent and elderly patients\u2014a comparative long-term analysis","volume":"10","author":"Andereggen","year":"2023","journal-title":"Front Surg"},{"key":"10.1016\/j.beem.2026.102082_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11102-023-01337-0","article-title":"Giant prolactinomas, a detailed analysis of 196 adult cases","volume":"26","author":"Billion","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s42000-021-00307-0","article-title":"Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience","volume":"20","author":"Cander","year":"2021","journal-title":"Hormones"},{"key":"10.1016\/j.beem.2026.102082_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4158\/EP-2018-0392","article-title":"Management and outcomes of giant prolactinoma: a series of 71 patients","volume":"25","author":"Hamidi","year":"2019","journal-title":"Endocr Pr"},{"key":"10.1016\/j.beem.2026.102082_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1055\/a-0752-0741","article-title":"Giant prolactinoma in men: clinical features and therapeutic outcomes","volume":"50","author":"Iglesias","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2026.102082_bib12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas?","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib13","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2016-2008","article-title":"Dopamine agonists can reduce cystic prolactinomas","volume":"101","author":"Faje","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clineuro.2016.01.029","article-title":"Hypopituitarism patterns among adult males with prolactinomas","volume":"144","author":"Peng","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.beem.2026.102082_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1742-1241.2011.02662.x","article-title":"Clinical significance of anaemia associated with prolactin-secreting pituitary tumours in men","volume":"65","author":"Iglesias","year":"2011","journal-title":"Int J Clin Pr"},{"key":"10.1016\/j.beem.2026.102082_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejim.2008.11.012","article-title":"Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists","volume":"20","author":"Kars","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.beem.2026.102082_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01137.x","article-title":"Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas","volume":"53","author":"George","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2026.102082_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00701-002-0938-1","article-title":"Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas","volume":"144","author":"Kristof","year":"2002","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.beem.2026.102082_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib22","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40618-025-02559-8","article-title":"Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study","volume":"48","author":"Detomas","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2026.102082_bib23","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.3390\/jcm14186656","article-title":"Risk-stratifying pituitary adenoma treatment: a cohort analysis and risk prediction of hypopituitarism","volume":"14","author":"Agha","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.beem.2026.102082_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib25","article-title":"Gamma knife radiosurgery (GKRS) for patients with prolactinomas: long-term results from a single-center experience","volume":"26","author":"Li","year":"2020","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"10.1016\/j.beem.2026.102082_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11102-019-00971-x","article-title":"Role of gamma knife radiosurgery in the treatment of prolactinomas","volume":"22","author":"Je\u017ekov\u00e1","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib27","first-page":"538","article-title":"Stereotactic radiosurgery outcomes in medically and surgically failed or nonsurgical candidates with medically failed prolactinomas: a systematic review and meta-analysis","volume":"84","author":"Yagnik","year":"2022","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"10.1016\/j.beem.2026.102082_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3171\/2019.4.JNS183443","article-title":"The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study","volume":"133","author":"Hung","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.beem.2026.102082_bib29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11102-018-0898-y","article-title":"Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study","volume":"21","author":"Liu","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11102-022-01219-x","article-title":"Endocrine disorders after primary gamma knife radiosurgery for pituitary adenomas: a systematic review and meta-analysis","volume":"25","author":"Palmisciano","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2015.36","article-title":"New insights in prolactin: pathological implications","volume":"11","author":"Bernard","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-020-02388-0","article-title":"High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?","volume":"70","author":"Espinosa-C\u00e1rdenas","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11102-024-01493-x","article-title":"Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma","volume":"28","author":"Detomas","year":"2025","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/biomedicines13051125","article-title":"Impact of tumor size on prolactinoma characteristics and treatment outcomes: a study of a Tunisian Cohort","volume":"13","author":"Elleuch","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.beem.2026.102082_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-025-04433-2","article-title":"Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists","author":"Zhang","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","article-title":"Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists","volume":"27","author":"Constantinescu","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib37","first-page":"65","article-title":"The place of surgery in the management of prolactin secreting adenomas","volume":"20","author":"Rotariu","year":"2024","journal-title":"Acta Endocrinol Buch Rom 2005"},{"key":"10.1016\/j.beem.2026.102082_bib38","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","article-title":"Long-term follow-up of 84 patients with giant prolactinomas\u2014a Swedish Nationwide Study","volume":"108","author":"Himonakos","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","article-title":"Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists","volume":"25","author":"Al Dahmani","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib40","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","article-title":"Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas","volume":"11","author":"Andereggen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2026.102082_bib41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cen.14541","article-title":"Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: does size really matter?","volume":"95","author":"Rudman","year":"2021","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/1179551420926181","article-title":"Clinical features, therapeutic trends, and outcome of giant prolactinomas: a single-center experience over a 12-year period","volume":"13","author":"Almalki","year":"2020","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2026.102082_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","article-title":"Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health","volume":"97","author":"Andereggen","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.beem.2026.102082_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2026.102082_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","article-title":"Male prolactinomas presenting with normal testosterone levels","volume":"17","author":"Shimon","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?","volume":"79","author":"Karavitaki","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11102-010-0251-6","article-title":"Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression","volume":"14","author":"Shimon","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib49","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2265.2003.01770.x","article-title":"Giant prolactinomas in men: efficacy of cabergoline treatment","volume":"58","author":"Corsello","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000489264","article-title":"Interpretation of serum gonadotropin levels in hyperprolactinaemia","volume":"107","author":"Abbara","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2026.102082_bib51","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-025-04215-w","article-title":"Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study","volume":"89","author":"Rudman","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","article-title":"The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males","volume":"64","author":"De Rosa","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib53","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1323","article-title":"12342 retrospective multicenter study of prolactinomas in men","volume":"8","author":"Guitelman","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2026.102082_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1025377816769","article-title":"Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function","volume":"5","author":"Sibal","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ando.2021.11.005","article-title":"Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma","volume":"83","author":"Telci Caklili","year":"2022","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib56","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae135","article-title":"Increase in testosterone levels and improvement of clinical symptoms in eugonadic men with a prolactin-secreting adenoma","volume":"8","author":"Carlier","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2026.102082_bib57","article-title":"Anemia in patients with pituitary adenomas: prevalence and correlation with hypopituitarism","volume":"17","author":"Paix\u00e3o C\u00f4rtes Aguiar","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.beem.2026.102082_bib58","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/andr.13428","article-title":"Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men","volume":"11","author":"Rudman","year":"2023","journal-title":"Andrology"},{"key":"10.1016\/j.beem.2026.102082_bib59","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib61","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12020-018-1652-y","article-title":"Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery","volume":"62","author":"Yi","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib63","doi-asserted-by":"crossref","first-page":"e4551","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib64","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","article-title":"Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma","volume":"25","author":"Rudman","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11102-025-01548-7","article-title":"Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia","volume":"28","author":"Milioto","year":"2025","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"key":"10.1016\/j.beem.2026.102082_bib68","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12020-017-1247-z","article-title":"Hypersexuality in men with prolactinomas treated with dopamine agonists","volume":"56","author":"Bancos","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib69","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2003-030852","article-title":"Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence","volume":"89","author":"De Rosa","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102082_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.fertnstert.2021.11.037","article-title":"Evolution of the WHO \u201cSemen\u201d processing manual from the first (1980) to the sixth edition (2021)","volume":"117","author":"Wang","year":"2022","journal-title":"Fertil Steril"},{"key":"10.1016\/j.beem.2026.102082_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11102-025-01497-1","article-title":"Outcomes in surgical management of microprolactinomas: an international multi-institutional series","volume":"28","author":"Golub","year":"2025","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12020-016-1042-2","article-title":"Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience","volume":"54","author":"Yedinak","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib73","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ando.2016.07.004","article-title":"Long-term outcome of macroprolactinomas","volume":"77","author":"K\u00e9p\u00e9n\u00e9kian","year":"2016","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib74","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.3390\/cancers13215374","article-title":"Efficacy and Cerebrospinal Fluid Rhinorrhea after Cabergoline Treatment in Patients with Bioactive Macroprolactinoma","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2026.102082_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12020-017-1458-3","article-title":"Microsurgical therapy of pituitary adenomas","volume":"59","author":"Mortini","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102082_bib76","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000022079","article-title":"Influence of age on the clinical presentation of prolactinomas in male patients","volume":"45","author":"Delgrange","year":"1999","journal-title":"Gerontology"},{"key":"10.1016\/j.beem.2026.102082_bib77","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/EJE-21-0293","article-title":"Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study","volume":"185","author":"Baussart","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ando.2021.11.008","article-title":"Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience","volume":"83","author":"Lasolle","year":"2022","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2026.102082_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.wneu.2010.05.007","article-title":"Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas","volume":"74","author":"Tanaka","year":"2010","journal-title":"World Neurosurg"},{"key":"10.1016\/j.beem.2026.102082_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s11102-018-0891-5","article-title":"IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas","volume":"21","author":"Akirov","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12902-024-01622-4","article-title":"Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight","volume":"24","author":"Caprio","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2026.102082_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2025.101669","article-title":"Dynamic changes in IGF-1 levels during cabergoline therapy in prolactinoma","volume":"82","author":"Demir","year":"2025","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.beem.2026.102082_bib83","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","article-title":"Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases","volume":"158","author":"Akin","year":"2016","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.beem.2026.102082_bib84","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists","volume":"14","author":"Babey","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2026.102082_bib85","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/endrev\/bnad010","article-title":"Syndrome of inappropriate antidiuresis: from pathophysiology to management","volume":"44","author":"Warren","year":"2023","journal-title":"Endocr Rev"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:10Z","timestamp":1788866350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521690X26000035"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102082","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypopituitarism in patients with prolactinomas: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102082"}}